Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going.

And here is our regular feature in which we highlight a different person each week. This time around, we note that Protillion Biosciences hired Robert Hollingsworth as chief scientific officer. Previously, he held the same role at Shoreline Therapeutics and, before that, he worked at Pfizer, where he was vice president and chief scientific officer of cancer vaccines and immunotherapeutics.

But all work and no play can make for a dull chief scientific officer.